RT @ByAmyBrown: Re ELAD Alzheimer's trial, $NVO's CSO says secondary cognitive measures might be too subtle to expect much, points out that…
Re ELAD Alzheimer's trial, $NVO's CSO says secondary cognitive measures might be too subtle to expect much, points out that primary endpoint is major readout: change in cerebral glucose metabolic rate. https://t.co/WtM8nBuuUk
RT @OxPsychiatry: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised co…
@mancunianmedic
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). https://t.co/8AoA8gipkr
New addition to the repository 📄 "Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)" #alzheimers #NHCStaffPub https://t.co/QWQzbPqh7X
Open Access UCL Research: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study) https://t.co/UD3dWveQDr
RT @DanielJDrucker: The exploratory trials examining the therapeutic potential for GLP-1 analogues in Alzheimer’s disease are coming. https…
RT @DanielJDrucker: The exploratory trials examining the therapeutic potential for GLP-1 analogues in Alzheimer’s disease are coming. https…
RT @DanielJDrucker: The exploratory trials examining the therapeutic potential for GLP-1 analogues in Alzheimer’s disease are coming. https…
RT @DanielJDrucker: The exploratory trials examining the therapeutic potential for GLP-1 analogues in Alzheimer’s disease are coming. https…
Finally #DIADEM
The exploratory trials examining the therapeutic potential for GLP-1 analogues in Alzheimer’s disease are coming. https://t.co/vBMntBuylU #trialsjournal